Umbilical-Cord-Derived Mesenchymal Stem Cells Injection for Chronic Radiation Proctitis

Last updated: June 20, 2024
Sponsor: Jiangsu Topcel-KH Pharmaceutical Co., Ltd.
Overall Status: Active - Recruiting

Phase

1/2

Condition

Ulcerative Colitis (Pediatric)

Hemorrhoids

Rectal Disorders

Treatment

Mesenchymal Stem Cells (MSCs)

Clinical Study ID

NCT06438809
TH-SC01-RP-I/II-03
  • Ages 18-79
  • All Genders

Study Summary

A Phase I/II study to evaluate the safety and preliminary efficacy of human umbilical cord-derived mesenchymal stem cell injection for the treatment of chronic radiation proctitis.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Fully understand and sign the informed consent form;

  2. Age ≥18 years and <80 years;

  3. Good physical condition (WHO performance status score 0-1);

  4. Pathologically diagnosed with pelvic malignant tumors and received radiotherapy;

  5. Diagnosed with chronic radiation proctitis after at least 6 months of endoscopicexamination following the completion of radiotherapy and ineffective conventionaltreatment;

  6. Screening period LENT-SOMA score ≥1;

  7. Subjects and their spouses or partners have no plans for conception from screeningto 6 months after the end of the trial, no plans for sperm or egg donation, andagree to use effective non-pharmacological contraceptive measures during the trial.

Exclusion

Exclusion Criteria:

  1. Patients with severe liver or kidney dysfunction during the screening period;

  2. Patients with severe congestive heart failure or coronary artery disease during thescreening period;

  3. Patients with allergic constitution or severe systemic immune diseases;

  4. Patients with active gastrointestinal bleeding or acute intestinal obstructionduring the screening period;

  5. Pregnant patients;

  6. Patients with rectal stenosis or fistula formation requiring surgical treatment thatlimits endoscopic therapy;

  7. Patients with a screening period LENT-SOMA score of 4;

  8. Patients with tumor recurrence or metastasis;

  9. Patients currently participating in other clinical trials at the time of screeningor who have not been out of another clinical trial for less than 1 month;

  10. Other situations deemed unsuitable for inclusion in this study by the investigator.

Study Design

Total Participants: 24
Treatment Group(s): 1
Primary Treatment: Mesenchymal Stem Cells (MSCs)
Phase: 1/2
Study Start date:
May 24, 2024
Estimated Completion Date:
May 31, 2025

Study Description

Radiation therapy is frequently used to treat pelvic cancers such as anal, cervical, prostate, and rectal cancer. While effective in controlling local tumors, it can also cause collateral damage to the gastrointestinal tract. The rectum is particularly vulnerable to radiation damage due to its fixed position in the pelvis. In the acute phase, radiation can lead to proctitis, an inflammatory condition characterized by mucosal ulceration, edema, and loss of microvilli. Patients typically present within three months of radiation therapy with symptoms like diarrhea, urgency, and tenesmus. Chronic radiation proctitis can either follow the acute phase or appear after a symptom-free period, typically 8 to 12 months post-radiation treatment. This chronic condition results from radiation-induced small-vessel injury, causing ischemia, obliterative endarteritis, fibrosis, and neovascularization. Rectal bleeding is a common symptom of chronic radiation proctitis.

Clinical studies have demonstrated that mesenchymal stem cell (MSC) treatment offers significant benefits, including anti-inflammatory, immune modulation, and tissue repair effects. Recent research indicates that intralesional injection of MSC is effective in treating radiation proctitis, reducing pain and bleeding without causing severe adverse events. This suggests that MSC treatment could be a promising option for radiation proctitis.

This is a phase I/II study designed to evaluate the safety and preliminary efficacy of MSC treatment for radiation proctitis. Patients will be followed up for 24 months after treatment.

Connect with a study center

  • Jinling Hospital

    Nanjing, Jiangsu 210016
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.